Importance of blood cellular genomic profile in coronary heart disease

Journal of Biomedical Science

Volumn 13, Issue 1, 2006, Pages 17-26

  Baba, M Iqbal ^a   Kaul, Deepak ^a   Grover, Anil ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Blood; Cellular genomics; Coronary heart disease; Interrelationship; Lipid

Indexed keywords

ATORVASTATIN; CD36 ANTIGEN; COMPACTIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIVER X RECEPTOR ALPHA; LOW DENSITY LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD CELL; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORRELATION ANALYSIS; DEMOGRAPHY; DISEASE SEVERITY; DRUG EFFECT; GENE EXPRESSION; GENETIC TRANSCRIPTION; GENOMICS; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; IN VITRO STUDY; IN VIVO STUDY; ISCHEMIC HEART DISEASE; LABORATORY TEST; LIPID BLOOD LEVEL; MALE; MONONUCLEAR CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SCORING SYSTEM; STATISTICAL ANALYSIS;

ADULT; AGED; ANTIGENS, CD36; CORONARY DISEASE; DNA-BINDING PROTEINS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENOMICS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, LDL; RNA, MESSENGER; STATISTICS;

EID: 31544436050     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1007/s11373-005-9041-y     Document Type: Article

References (30)

1. Ross R., The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362: 801-809, 1993.
2. Kutuk O. and Basaga H., Inflammation meets oxidation: NF-κB as a mediator of initial lesion development in atherosclerosis. Trends. Mol. Med. 9: 549-557, 2003.
3. Lazar M.A., Progress in cardiovascular biology: PPARs for the course. Nat. Med. 7: 23-24, 2001.
4. Devchand P.R., Keller H., Peter J.M., Vazquez M., Gonzalez F.J. and Wahli W., The PPARα-leukotriene B4 pathway to inflammation control. Nature 384: 39-43, 1996.
5. Ricote M., Huang J.T., Welch J.S. and Glass C.K., The peroxisome proliferator- activated receptor-gamma as a regulator of monocyte/macrophage function. J. Leukoc. Biol. 66: 733-739, 1999.
6. Tontonoz P., Nagy L., Alvarez J., Thomazy V. and Evans R.M., PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93: 241-252, 1998.
7. Chinetti G., Gbaguidu F.G., Griglio S., Mallat Z., Antonucci M., Poulain P., Chapman J., Fruchart J.C., Tedgui A., Najib- Fruchart J. and Staels B., CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. Circulation 101: 2411-2417, 2000.
8. Kersten S., Desvergne B. and Walter W., Roles of PPARs in health and disease. Nature 405: 421-424, 2000.
9. Kaul D., Molecular link between cholesterol, cytokines and atherosclerosis. Mol. Cell. Biochem. 219: 65-71, 2001.
10. Repa J.J., Liong G. and Ou J., Regulation of mouse sterol regulatory element binding protein-Ic (SREBP-Ic) gene by oxysterol receptors LXRα and LXRβ. Genes Develop. 14: 2819-2830, 2000.
11. Wilson T.M., Brown P.J., Sternbach D.D. and Henke B.R., The PPARs: from orphan receptors to drug delivery. J. Med. Chem. 43: 527-551, 2000.
12. Repa J.J. and Mangelsdorf D.J., The liver X receptor gene team: Potential new players in atherosclerosis. Nat. Med. 8: 1243-1248, 2002.
13. Sugawara A., Urono A., Kudo M., Ikeda Y., Sato K., Taniyama Y., Ito S. and Takeuchi K., Transcriptional suppression of thromboxane receptor gene by peroxisome proliferator-activated receptor-gamma via an interaction with Sp1 in vascular smooth muscle cells. J. Biol. Chem. 277: 9676-9683, 2002.
14. Nagy L., Tontonoz P., Alvarez J.G., Chen H. and Evans R.M., Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ. Cell 93: 229-240, 1998.
15. Executive summary of the third report of the National Cholesterol Education Program (NCEP), Expert panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adults Treatment Panel III). JAMA 285: 2486-97, 2001.
16. Gensini G.G., A more meaningful scoring system for determining the severity of coronary heart disease. Am. J. Cardiol. 51: 606-607, 1983.
17. Boyum A., Ficoll-Hypaque method for separating mononuclear cells and granulocytes from human blood. Scand. J. Clin. Lab. Invest. 77(Suppl) 57-62, 1968.
18. Chomczynski P. and Sacchi N., Single step method of RNA isolation by acid guanidium thiocyanate phenol chloroform extraction. Anal. Biochem. 162: 156-159, 1987.
19. Auboeuf D., Reiusset J., Fajas L., Vallier P., Frering V., Riou J.P., Staels B., Auwerx J., Laville M. and Vidal H., Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptorα in humans. Diabetes 46: 1319-1327, 1997.
20. 1 downregulates CD36 and scavenger receptor A but upregulates LOX-1 in human macrophages. Am. J. Physiol. Heart. Circ. Physiol. 278: H1042-H1048, 2000.
21. Xu D., Gruber A., Peterson C. and Pisa P., Telomerase activity and the expression of telomerase components in acute myelogenous leukemia. Br. J. Haematol. 102: 1367-1375, 1998.
22. Chawla A., Barak Y., Nagy L., Liao D., Tontonoz P. and Evans R.M., PPARγ dependent and independent effects on macrophage gene expression in lipid metabolism and inflammation. Nat. Med. 7: 48-52, 2001.
23. Duval C., Chinetti G., Trottein F., Fruchant J.C. and Staels B., The role of PPARs in atherosclerosis. Trends. Mol. Med. 8: 422-430, 2002.
24. Chinetti G., Lestavel S., Bocher V., Remaley A.T., Neve B., Torra I.P., Teissier E., Minnich A., Jaye M., Duverger N., Brewer H.B., Fruchart J.C., Clavey V. and Staels B., PPARα and PPARα activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat. Med. 7: 53-58, 2001.
25. Meissner M., Stein M., Urbich C., Reisinger K., Suske G., Staels B., Kaufmann R. and Gille J., PPARα activators inhibit vascular endothelial growth factor receptor-2 expression by repressing Sp1-dependent DNA binding and transactivation. Circ. Res. 94: 324-332, 2004.
26. Sanchez H.B., Yieh L. and Osborne T.F., Cooperation by sterol regulatory element-binding protein and Sp1 in sterol regulation of low density lipoprotein receptor gene. J. Biol. Chem. 270: 1161-1169, 1995.
27. Jaye M., LXR agonists for the treatment of atherosclerosis. Curr. Opin. Investig. Drugs. 9: 1053-1058, 2003.
28. Tontonoz P. and Mangelsdorf D.J., Liver X receptor signaling pathways in cardiovascular disease. Mol. Endocrinol. 17: 985-993, 2003.
29. Han J., Zhou X., Yokohoma T., Hajjar D.P., Goto A.M. and Nicholson D.V.M., Pivastatin downregulates expression of the macrophage type B scavenger receptor, CD36. Circulation 109: 790-796, 2004.
30. Joseph S.B., McKilligin E., Pei L., Collins A.R., Laffitte B.A., Chen M., Noh G., Goodman J., Hagger G.N., Tran J., Tippin T.K., Wang X., Lusis A.J., Hsueh W.A., Law R.E., Collins J.L., Willson T.M. and Tontonoz P., Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc. Natl. Acad. Sci. USA 11: 7604-7609, 2002.